# Addex Therapeutics Ltd.: overview ADXN · Nasdaq · CIK 1574232 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/adxn.md) · [Financials](/companies/adxn/financials.md) · [Filings](/companies/adxn/filings.md) · [Insiders](/companies/adxn/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters Not reported. ## Last five fiscal years | Line item | Unit | FY2020 (2020-12-31) | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [3.6](/filings/0001104659-23-038581.md) | [2.9](/filings/0001104659-24-048532.md) | [1.4](/filings/0001104659-25-049380.md) | [1.6](/filings/0001104659-25-049380.md) | [0.4](/filings/0001104659-25-049380.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(338.9%)](/filings/0001104659-23-038581.md) | [(531.7%)](/filings/0001104659-24-048532.md) | [(741.0%)](/filings/0001104659-25-049380.md) | [(139.1%)](/filings/0001104659-25-049380.md) | [(681.8%)](/filings/0001104659-25-049380.md) | | Net margin | % | [(355.9%)](/filings/0001104659-23-038581.md) | [(526.4%)](/filings/0001104659-24-048532.md) | [(1462.6%)](/filings/0001104659-25-049380.md) | [(654.5%)](/filings/0001104659-25-049380.md) | [1746.0%](/filings/0001104659-25-049380.md) | | Diluted EPS | $ per share | [(0.48)](/filings/0001104659-23-038581.md) | [(0.45)](/filings/0001104659-24-048532.md) | [(0.46)](/filings/0001104659-25-049380.md) | [(0.14)](/filings/0001104659-25-049380.md) | [0.07](/filings/0001104659-25-049380.md) | | Free cash flow | $m | [(12.2)](/filings/0001104659-23-038581.md) | [(14.7)](/filings/0001104659-24-048532.md) | [(16.4)](/filings/0001104659-25-049380.md) | [(8.0)](/filings/0001104659-25-049380.md) | [(5.4)](/filings/0001104659-25-049380.md) | - Revenue. XBRL Revenue: ifrs-full:RevenueFromContractsWithCustomers. - Gross margin (gross profit / revenue). XBRL Revenue: ifrs-full:RevenueFromContractsWithCustomers. - Operating margin (operating income / revenue). XBRL Operating income: ifrs-full:ProfitLossFromOperatingActivities; Revenue: ifrs-full:RevenueFromContractsWithCustomers. - Net margin (net income / revenue). XBRL Net income: ifrs-full:ProfitLoss; Revenue: ifrs-full:RevenueFromContractsWithCustomers. - Diluted EPS. XBRL Diluted EPS: ifrs-full:DilutedEarningsLossPerShare. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: ifrs-full:CashFlowsFromUsedInOperatingActivities; Capital expenditure: ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/adxn/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $268 | 47 | | New +47 | | [SBI Securities Co., Ltd.](/funds/1851815.md) | 2026-06-30 | $6 | 1 | | Unchanged | ## Recent filings [All 275 filings](/companies/adxn/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-29 | 06:05 ET | [6-K](/filings/0001171843-26-006946.md) | Report of a foreign private issuer, period 2026-10-29 | 0001171843-26-006946 | | 2026-10-08 | 06:05 ET | [6-K](/filings/0001171843-26-006524.md) | Report of a foreign private issuer, period 2026-10-08 | 0001171843-26-006524 | | 2026-10-02 | 06:05 ET | [6-K](/filings/0001171843-26-006345.md) | Report of a foreign private issuer, period 2026-10-02 | 0001171843-26-006345 | | 2026-09-28 | 07:06 ET | [6-K](/filings/0001104659-26-111142.md) | Report of a foreign private issuer, period 2026-06-30 | 0001104659-26-111142 | | 2026-09-25 | 06:05 ET | [6-K](/filings/0001171843-26-006225.md) | Report of a foreign private issuer, period 2026-09-25 | 0001171843-26-006225 | | 2026-09-04 | 16:00 ET | [SCHEDULE 13D/A](/filings/0001104659-26-105480.md) | Ownership report, active investor, amended | 0001104659-26-105480 | | 2026-08-27 | 06:00 ET | [SCHEDULE 13D/A](/filings/0001104659-26-101798.md) | Ownership report, active investor, amended | 0001104659-26-101798 | | 2026-08-26 | 06:05 ET | [6-K](/filings/0001171843-26-005744.md) | Report of a foreign private issuer, period 2026-08-26 | 0001171843-26-005744 | | 2026-07-08 | 06:05 ET | [6-K](/filings/0001171843-26-004524.md) | Report of a foreign private issuer, period 2026-07-08 | 0001171843-26-004524 | | 2026-06-30 | 06:05 ET | [6-K](/filings/0001171843-26-004375.md) | Report of a foreign private issuer, period 2026-06-30 | 0001171843-26-004375 | ## Latest annual report [Form 20-F for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-062447.md), filed May 15, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1574232 - Tickers: ADXN - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: V8 - Filer category: Non-accelerated filer Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 06:06 ET. No prices; not investment advice.